Neuropeptide receptor status in human tumor cell lines.
Tumor types expressing a neuroendocrine phenotype secrete neuropeptides with paracrine or autocrine growth factor activity. The efficacy of these paracrine or autocrine loops depends on the expression of specific receptors on tumor cells. Once specific receptors are identified, specific neuropeptide antagonists disrupting paracrine and autocrine loops could be potential treatments in neuropeptide-secreting tumors. In the present study, 11 human tumor cell lines representing astrocytoma, lymphoma, and pancreatic, prostate, lung and colon carcinomas were examined for expression of five different neuropeptide receptors (cholecystokinin, neurotensin, vasopressin, tachykinine substance P and cannabinoid) using RT-PCR and radioligand binding. The presence of various neuropeptide receptors in different human cancer cell lines supports development of new antitumor treatments based on disruption of neuropeptide autocrine growth pathways.
Institute for Drug Development, Cancer Therapy Research Center, San Antonio, TX 78245, USA.
T
T
Petit
K K
KK
Davidson
R A
RA
Lawrence
D D
DD
von Hoff
E
E
Izbicka
D002455:Cell Division / Q000187:drug effects; D017931:DNA Primers / Q000737:chemistry; D006801:Humans; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000378:metabolism; D011869:Radioligand Assay; D018013:Receptors, Neuropeptide / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured / Q000378:metabolism*
D017931:DNA Primers; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D018013:Receptors, Neuropeptide